An executive order by Trump rolled back some efforts by the Biden administration to control Medicare costs but it didn't ...
At least three government lawyers working on defending a major Biden-era drug pricing law were laid off in mass cuts across ...
This year, people on Medicare Part D will not have to pay more than $2,000 in out-of-pocket drug expenditures — and that ...
The Inflation Reduction Act of 2022 marked a significant shift in US health care policy, granting the Centers for Medicare and Medicaid Services (CMS) the authority to establish a program to negotiate ...
Prior authorization reforms, increased biosimilar access and the future of the Medicare drug price negotiation program are ...
Older Americans have ways to protect against high out-of-pocket health care costs, but it’s important to understand the trade ...
The Trump administration, perhaps surprisingly, chose to defend the legality of the Inflation Reduction Act’s (IRA’s) drug ...
Robert F. Kennedy Jr. faced a tough confirmation process, seeming unable to understand Medicare and Medicaid. Yet the Senate ...
GenBioPro, the largest manufacturer of abortion pills in the U.S., is wading into a federal court case over abortion access ...